Stock market data from financial news sources or stock market platforms

Lexeo Therapeutics Reports Positive Interim Data for LX2006 with 18.3% LVMI Reduction at 18 Months

Jul 15, 2024, 10:03 AM

Lexeo Therapeutics has announced positive interim Phase 1/2 clinical data for its gene therapy, LX2006, aimed at treating Friedreich Ataxia Cardiomyopathy. The data revealed a mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants who had elevated LVMI at baseline. Baird remains bullish on Lexeo, noting that levels approaching 20% would be a significant milestone. The Baird report suggests that the LX2006 update can provide further proof-of-concept. Despite some early data showing promise, there are concerns about the clarity of the results.